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ABSTRACT
Objectives Osteoarthritis (OA) has a complex aetiology
with a strong genetic component. Genome-wide
association studies implicate several nuclear genes in the
aetiology, but a major component of the heritability has
yet to be deﬁned at the molecular level. Initial studies
implicate maternally inherited variants of mitochondrial
DNA (mtDNA) in subgroups of patients with OA based
on gender and speciﬁc joint involvement, but these
ﬁndings have not been replicated.
Methods The authors studied 138 maternally inherited
mtDNA variants genotyped in a two cohort genetic
association study across a total of 7393 OA cases from
the arcOGEN consortium and 5122 controls genotyped in
the Wellcome Trust Case Control consortium 2 study.
Results Following data quality control we examined 48
mtDNA variants that were common in cohort 1 and
cohort 2, and found no association with OA. None of the
phenotypic subgroups previously associated with mtDNA
haplogroups were associated in this study.
Conclusions We were not able to replicate previously
published ﬁndings in the largest mtDNA association study
to date. The evidence linking OA to mtDNA is not
compelling at present.
INTRODUCTION
Osteoarthritis (OA) is the most common
age-related joint disease. The pathogenesis of OA is
complex, with several environmental and genetic
factors implicated in the aetiology.1 Genome-wide
association studies implicate several nuclear genes
in the risk of developing OA, but a major compo-
nent of the heritability remains unexplained.2
Mitochondria are intracellular organelles
involved in the synthesis of ATP, the principal
source of energy within cells. Several lines of evi-
dence implicate mitochondrial dysfunction in the
pathogenesis of OA, including the disruption of
respiratory chain activity in chondrocytes,3 the
increased production of reactive oxygen species
which compromise chondrocyte function4 5 and a
central role in one apoptotic pathway.6
Mitochondria contain multiple copies of the
16.5 kb mitochondrial genome (mitochondrial
DNA (mtDNA)). MtDNA codes for 13 essential
respiratory chain proteins and the RNAs required
for intramitochondrial protein synthesis. Point
mutations of mtDNA compromise oxidative phos-
phorylation and are a major cause of human
disease.7 This raises the possibility that more
subtle polymorphic variants contribute to genetic
susceptibility of common complex traits, including
OA. Being strictly maternally inherited, mtDNA
undergoes negligible intermolecular recombination.
Speciﬁc sequence variants that occurred 10–
40 000 years ago deﬁne clades of the European
mtDNA phylogeny called mtDNA haplogroups,
each containing both distinct and shared genetic
variants.8 Two studies have reported an association
between different mtDNA haplogroups and OA,
with one describing a reduced risk of knee OA
with haplogroups J (deﬁned by m.4216T>C and
m.10398A>G) and JT (m.4216T>C), and another
describing a reduced risk of hip OA with
haplogroups J (deﬁned by m.4216T>C and
m.10398A>G) and J1c (m.14798T>C).9 10
However, each study lacked the power and reso-
lution to reliably detect an association with all but
the most common haplogroups. Moreover, despite
being from the same geographic location, the
studies reported different haplogroup associations
with different joint involvement in OA for speciﬁc
genders.9 10 While these data support the potential
role of mtDNA in determining OA risk, the
absence of direct replication means that the role of
mtDNA in OA is thus uncertain, and the
joint-speciﬁc risk is difﬁcult to explain based on
the proposed mechanism. To address this issue, we
carried out a two phase study of 138 mtDNA var-
iants in 7393 OA cases and 5122 controls as part
of the arcOGEN consortium.
METHODS
We performed a two stage genetic association
study. The cases were part of the arcOGEN study,
and the controls were part of the Wellcome Trust
Case Control Consortium 2 (WTCCC2) study,
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both ascertained as described previously.2 11 In cohort 1, 3093
cases (ARC1) were compared with 2640 controls from the 1958
Birth Cohort (WTCCC-58C). In cohort 2, 4300 cases (ARC2)
were compared with 2482 UK Blood Service controls
(WTCCC-NBS). All cases were genotyped using the Illumina
Human610 platform (Illumina, San Diego, California, USA).
All controls were genotyped on the Illumina 1.2M Duo plat-
form (Illumina). Individuals were excluded from subsequent
analysis if data were absent in >10% of single nucleotide poly-
morphism (SNP) (cohort 1 cases=0 and WTCCC-58C=44 and
cohort 2 cases=0 and WTCCC-NBS=11) and SNPs were
excluded if >10% of genotypes were absent (cohort 1=5 and
cohort 2=4).11 We excluded 30 SNPs (cohort 1=15 and cohort
2=21) with a study-wide missing data rate >5% or >1% for
SNPs with a study-wide minor allele frequency (MAF) <5%.11
Finally, 64 SNPs with MAF<1% were removed (cohort 1=53
and cohort 2=64). Subsequent analysis was restricted to a con-
cordant dataset of 62 mtDNA variants passing quality control
(QC) in both phases. Differential missingness tests between
cases and controls revealed signiﬁcant differences in 14 SNPs
(p=<10−4) reducing the ﬁnal number of experimental SNPs to
48. Statistical signiﬁcance was deﬁned as p<0.05 in both
phases. χ² And missingness were computed using PLINK v
2.050 (http://pngu.mgh.harvard.edu/purcell/plink/).12
Array genotypes were used to identify mtDNA haplogroup-
speciﬁc sequence motifs, when compared with the mtDNA ref-
erence sequence (see online supplementary materials and table
S1), allowing 98.48% of subjects to be successfully assigned to
a European haplogroup.
A principal components analysis (PCA )13 was performed on
the X : Y ratios of raw intensities for all SNPs for the combined
dataset of cases (n=7393) and controls (n=5122) using R. The
k-means function of the R cluster package was used to cluster
individuals into 5, 10, 15 and 20 groups using these PCA scores.
RESULTS
Using established QC criteria14 we rejected 90 SNPs, leaving 48
in both cohorts. There was no association between any
mtDNA variant passing QC and OA. Stratifying by gender,
joint involvement (knee or hip) and method of case ascertain-
ment (radiograph or arthroplasty) failed to reveal any signiﬁ-
cant associations (see online supplementary table S2).
We then studied mtDNA haplogroups using two independ-
ent approaches: (1) manual haplogroup calling based on phylo-
genetics (for methods see online supplementary table 1) and
(2) hypothesis-free approach based on raw ﬂuorescence intensities
in a principal components analysis. Analysis of mtDNA hap-
logroups between cases and controls failed to replicate previous
studies (table 1). Stratifying by gender, joint involvement (knee or
hip) and method of case ascertainment (radiograph or arthro-
plasty) failed to reveal any signiﬁcant associations with mtDNA
haplogroups (see online supplementary table S3). PCA analysis
identiﬁed the main mtDNA haplogroups previously identiﬁed
through phylogenetic analysis. These appear as clusters in
ﬁgure 1, where each cluster represents a major European mtDNA
haplogroup. However, there was no signiﬁcant difference in
cluster membership for any of the disease or control cohorts, or
when the cases and controls were pooled (ﬁgure 1, online
supplementary table S4). The data were only pooled after con-
ﬁrming that the allele frequencies were not signiﬁcantly different
between the two case groups or between the two control groups.
DISCUSSION
The previously reported haplogroup associations were with spe-
ciﬁc subgroups of OA patients, subcategorised based on gender
and/or speciﬁc joint involvement.9 10 Our study had >99%
power to detect these associations, and there was no signiﬁcant
difference in the frequency of the previously associated SNPs
between controls in the published studies9 10 and the controls
used in our study. The previously published results were based on
substantially smaller study groups than the ones we describe
here, raising the possibility that the published ﬁndings are a false
positive ﬁnding. On the other hand, the relative contribution of
speciﬁc mtDNA variants could vary in different ethnic groups,
possibly through an interaction with environmental factors and
different nuclear genes.15 In practice, this means that the speciﬁc
mtDNA variants which fail to show an association with disease
in this study could be associated with disease in a different ethnic
population. Geographic variation in allelic association could also
arise through homoplasy. Homoplasy is the recurrence of muta-
tions on different branches of the mtDNA phylogeny in different
parts of the world. Homoplasy accounts for up to 20% of
mtDNA variation, and often involves non-synonymous substitu-
tions.16 This raises the possibility that haplogroup markers tag
different homoplastic functional variants in different popula-
tions. If the homoplasies are having a functional effect, then this
would lead to different haplogroup associations in different
studies across the globe. Finally, it is possible that geographic dif-
ferences in the ﬁne detail of the sub-haplogroup structure of
mtDNA could account for inconsistencies between studies, as
Table 1 Frequency of mitochondrial DNA (mtDNA) haplogroups in osteoarthritis and control subjects
Hap F ACR1 F WTCCC-58C P F ARC2 F WTCCC-NBS P F cases F control p Value
H 1375 (44.5) 1160 (43.9) 5.97E−01 1887 (43.9) 1080 (43.5) 6.36E−01 3262 (44.1) 2240 (43.7) 6.67E−01
V 107 (3.5) 84 (3.2) 5.40E−01 133 (3.1) 86 (3.5) 4.25E−01 240 (3.2) 170 (3.3) 8.42E−01
J 335 (10.8) 311 (11.8) 2.81E−01 527 (12.3) 292 (11.8) 5.02E−01 862 (11.7) 603 (11.8) 8.25E−01
T 309 (10.0) 266 (10.1) 9.56E−01 449 (10.4) 227 (9.1) 7.50E−02 758 (10.3) 493 (9.6) 5.39E−01
U 440 (14.2) 334 (12.7) 7.20E−02 549 (12.8) 366 (14.7) 2.70E−02 989 (13.4) 700 (13.7) 7.35E−01
K 280 (9.1) 241 (9.1) 9.59E−01 362 (8.4) 216 (8.7) 7.32E−01 642 (8.7) 457 (8.9) 8.20E−01
W 56 (1.8) 46 (1.7) 8.30E−01 91 (2.1) 56 (2.3) 7.26E−01 147 (2.0) 102 (2.0) 3.38E−01
X 50 (1.6) 46 (1.7) 7.26E−01 76 (1.8) 35 (1.4) 2.53E-01 126 (1.7) 81 (1.6) 8.27E−01
I 88 (2.8) 99 (3.8) 5.80E−02 131 (3.0) 80 (3.2) 7.13E−01 219 (3.0) 179 (3.5) 1.19E−01
O 53 (1.7) 53 (2.0) 4.22E−01 95 (2.2) 44 (1.8) 2.11E−01 148 (2.0) 97 (1.9) 6.31E−01
Missing 6 59 11 19 17 78
Haplogroups determined manually, as described in the Methods section and online supplementary table S1.
Uncorrected χ² comparison of haplogroup frequencies showing: (i) cohort 1 (ARC1, n=3093 and controls WTCCC-58C, n=2640); (ii) cohort 2 (ARC2, n=4300 and controls
WTCCC-NBS, n=2482); and (iii) pooled arcOGEN cases (n=7393) and controls (n=5122). Hap=mtDNA haplogroup, F= frequency (percentage in brackets) and p=uncorrected
Pearson’s χ2 probability. For study and control group acronyms see the Methods section.
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described for Leber ’s hereditary optic neuropathy, where sub-
branches of haplogroup J are associated with either an increased
or decreased risk of visual failure in different populations, largely
due to speciﬁc differences in the cytochrome B protein
sequence.17 However, in the largest mtDNA association study to
date, we found no association between OA and the major
European mtDNA haplogroups in either cohort. If an association
does exist between OA and mtDNA, it is likely that this will only
be resolved through extensive genotyping, ideally at the whole
mtDNA level, in a much larger cohort of cases and controls and
should be consistent in more than one geographic region.
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Figure 1 Principal components analysis (PCA) performed on raw
ﬂuorescent intensities in the pooled data set of 7393 osteoarthritis (OA)
cases and 5122 controls. The PCA provided independent conﬁrmation
of the European haplogroup structure. There was no signiﬁcant
difference in the cluster distribution between OA cases and controls
(online supplementary table S4). 58C, WTCCC MRC 1958 birth cohort
control genotypes; ARC1, arcOGEN cohort 1; ARC2, arcOGEN cohort 2;
NBS, WTCCC national blood transfusion service control genotypes;
WTCCC, Wellcome Trust Case Control Consortium. This ﬁgure is only
reproduced in colour in the online version.
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